Susquehanna International Group’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Susquehanna International Group’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$253K	Buy	+9,770	New	+$251K	﹤0.01%	11245
2025 Q3	–	Sell	-13,602	Closed	-$45.2K	–	12951
2025 Q2	$45.2K	Buy	13,602 +2,880	+27%	+$8.52K	﹤0.01%	12143
2025 Q1	$33.2K	Buy	+10,722	New	+$50.5K	﹤0.01%	11981
2024 Q3	–	Sell	-6,734	Closed	-$79.8K	–	12359
2024 Q2	$79.8K	Buy	+6,734	New	+$106K	﹤0.01%	11175
2024 Q1	–	Sell	-1,101	Closed	-$19.8K	–	12595
2023 Q4	$19.8K	Buy	+1,101	New	+$16.9K	﹤0.01%	11977
2023 Q3	–	Sell	-3,837	Closed	-$242K	–	12355
2023 Q2	$242K	Buy	3,837 +1,316	+52%	+$71.7K	﹤0.01%	9881
2023 Q1	$125K	Buy	2,521 +1,012	+67%	+$53.4K	﹤0.01%	11086
2022 Q4	$43.4K	Sell	1,509 -600	-28%	-$24.9K	﹤0.01%	11467
2022 Q3	$99K	Buy	+2,109	New	+$107K	﹤0.01%	11713
2022 Q1	–	Sell	-639	Closed	-$48K	–	13364
2021 Q4	$48K	Buy	+639	New	+$50.2K	﹤0.01%	12570

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Susquehanna International Group's DMRA Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 9,770 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #11245 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in DMRA as recently as Q2 2025.

Susquehanna International Group first reported a position in DMRA in Q4 2021 and has held it in 10 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

Susquehanna International Group held 9,770 shares of Damora Therapeutics, Inc. Ordinary Shares worth $253K as of Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares was a new Susquehanna International Group position in Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11245 holding.
Susquehanna International Group first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2021 and has held it in 10 quarters since.
65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.